Novo and Lilly in race to invest the most in obesity drug production
Although both Novo Nordisk and Eli Lilly are making one billion-dollar investment after another in their production capacity, they are still deemed unable to meet the demand in the obesity market.
Even though Denmark’s Novo Nordisk has just planned to invest EUR 2.1bn in an expansion of the pharmaceutical company’s factory in France, an US-based Eli Lilly is planning to invest USD 2.5bn in a brand new German factory, pharmaceutical analyst at the investment bank SEB, Martin Parkhøi, still does not believe that the two rivals in the obesity market will reach a capacity that can saturate it.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
